CN105935359A - Virosaine A的哌嗪基和咪唑基衍生物的组合物在抗慢性阻塞性肺病药物中的应用 - Google Patents
Virosaine A的哌嗪基和咪唑基衍生物的组合物在抗慢性阻塞性肺病药物中的应用 Download PDFInfo
- Publication number
- CN105935359A CN105935359A CN201610274882.XA CN201610274882A CN105935359A CN 105935359 A CN105935359 A CN 105935359A CN 201610274882 A CN201610274882 A CN 201610274882A CN 105935359 A CN105935359 A CN 105935359A
- Authority
- CN
- China
- Prior art keywords
- compositions
- obstructive pulmonary
- pulmonary disease
- chronic obstructive
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 239000003814 drug Substances 0.000 title abstract description 8
- 229940079593 drug Drugs 0.000 title abstract description 5
- 125000002883 imidazolyl group Chemical group 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 15
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 15
- 210000004969 inflammatory cell Anatomy 0.000 claims description 12
- 210000002540 macrophage Anatomy 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 10
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 9
- 239000005482 chemotactic factor Substances 0.000 claims description 6
- 210000003714 granulocyte Anatomy 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 230000003448 neutrophilic effect Effects 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 claims description 3
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 22
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 235000019504 cigarettes Nutrition 0.000 description 7
- 230000007115 recruitment Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- FSDTUOKRYYZAQY-AEAJCJRFSA-N (1S,6S,8R,9R,12S,15R)-8-hydroxy-5,10-dioxa-11-azapentacyclo[7.6.0.02,6.06,12.011,15]pentadec-2-en-4-one Chemical compound O[C@@H]([C@@H]1ON23)C[C@@]45[C@@H]3CC[C@@H]2[C@@H]1C4=CC(=O)O5 FSDTUOKRYYZAQY-AEAJCJRFSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 208000035126 Facies Diseases 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 240000007003 Flueggea virosa Species 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000867909 Securinega Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- CFNHVUGPXZUTRR-UHFFFAOYSA-N CCCNCCN Chemical compound CCCNCCN CFNHVUGPXZUTRR-UHFFFAOYSA-N 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- ODJZWVFLHZHURI-UHFFFAOYSA-M [Br-].C(CCC)[P+](CCCC)(CCCC)CCCC.[NH4+].[Br-] Chemical compound [Br-].C(CCC)[P+](CCCC)(CCCC)CCCC.[NH4+].[Br-] ODJZWVFLHZHURI-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003889 oxyphil cell of parathyroid gland Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及有机合成和药物化学领域,具体涉及组合物、制备方法及其在制备抗慢性阻塞性肺病药物上的用途。本发明公开了一种组合物及其制备方法。药理学实验表明,本发明的组合物具有抗慢性阻塞性肺病的作用,具有开发抗慢性阻塞性肺病药物的价值。
Description
技术领域
本发明涉及有机合成和药物化学领域,具体涉及组合物、制备方法及其用途。
背景技术
慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一种全球范围内常见的慢性病,目前在全球死亡原因中排名第四,据世界卫生组织预测,到2020年,COPD将在全球疾病发病中排名第五,死亡原因中排名第三。
COPD是一种不完全可逆的气流受限特征的疾病,与肺部对有害气体或有毒颗粒的异常炎症反应有关,其慢性炎症反应遍及气道、肺实质和肺血管。参与COPD的细胞有中性粒细胞、T淋巴细胞和巨噬细胞等炎性细胞,当细胞被激活后释放多种炎性介质,如白三烯B4(LTB4)、白细胞介素8(IL-8)、RANTES、Eotaxin、肿瘤坏死因子α(TNFα)、基质金属蛋白酶9(MMP-9)等,参与肺实质破坏、肺血管等炎症反应。病理变化特征表现为肺泡腔炎性细胞(如巨噬细胞)浸润、小支气管和细支气管周围灶性炎性细胞浸润,肺组织边缘肺泡腔扩张、破坏,肺泡壁变宽,其上皮细胞肿胀、变圆、部分脱落。COPD与慢性支气管炎和肺气肿密切相关,但定义上有所不同,支气管哮喘与特应性***反应有关,其气流受限具可逆性(与慢性气管炎合并时会出现气流受限不完全可逆)。现在尚无药物能遏制COPD病情的进行性发展,其药物治疗的研究进展相当缓慢,目前临床常常将治疗哮喘的药物用于治疗COPD,由于COPD的发病机制不同于哮喘,难以取得满意的疗效。
从天然产物中寻找化合物或先导化合物并进行结构修饰获得其衍生物,从而得到高效低毒的潜在药物最有重要价值。
本发明涉及的化合物I是一个2012年发表(Bing-Xin Zhao et al.,2012.Virosaines A and B,Two New Birdcage-Shaped Securinega Alkaloids with anUnprecedented Skeleton from Flueggea virosa.Organic Letters 14(2012)3096–3099)的化合物,我们对化合物I进行了结构修饰,获得了两个新的衍生物即化合物III和化合物IV,并用化合物III和化合物IV制备了组合物并对该组合物抗慢性阻塞性肺病活性进行了评价,其具有抗慢性阻塞性肺病活性。
发明内容
本发明公开了一个新的组合物,该组合物由化合物III和化合物IV组成,该组合物中化合物III和化合物IV的质量百分数分别为55%和45%。
本发明公开的组合物可以制成药学上可接受的盐或药学上可接受的载体。
长期吸烟是最常见的人类COPD致病因素,我们实验室用香烟诱导模拟小鼠COPD模型,拟研究本发明组合物对香烟诱导的小鼠COPD的缓解作用。
本发明目的在于提供本发明组合物在制备抗COPD疾病药物中的应用。本发明组合物在剂量10mg/kg下灌胃给药,对香烟诱导的COPD小鼠BALF中炎性细胞因子TNFα的生成有抑制作用;对趋化因子RANTES的分泌有抑制作用;对BALF中的炎性细胞的募集有抑制作用。
以下通过实施例对本发明作进一步详细的说明,但本发明的保护范围不受具体实施例的任何限制,而是由权利要求加以限定。
具体实施方式
实施例1化合物Virosaine A的制备
化合物Virosaine A(I)的制备方法参照Bing-Xin Zhao等人发表的文献(Bing-Xin Zhao et al.,2012.Virosaines A and B,Two New Birdcage-ShapedSecurinega Alkaloids with an Unprecedented Skeleton from Flueggea virosa.OrganicLetters 14(2012)3096–3099)的方法。
实施例2 Virosaine A的O-溴乙基衍生物(II)的合成
将化合物I(235mg,1.00mmol)溶于20mL苯,向溶液中加入四丁基溴化铵(TBAB)(0.08g),1,2-二溴乙烷(3.760g,20.00mmol)和5mL的50%氢氧化钠溶液。混合物在35摄氏度搅拌8h。8h之后将反应液倒入冰水中,立即用二氯甲烷萃取两次,合并有机相溶液。然后对有机相溶液依次用水和饱和食盐水洗涤3次,再用无水硫酸钠干燥,最后减压浓缩去除溶剂得到产物粗品。产物粗品用硅胶柱层析纯化(流动相为:石油醚/丙酮=100:1.0,v/v),收集棕色集中洗脱带并挥去溶剂即得到化合物II的棕色粉末(261mg,78%)。
1H NMR(500MHz,DMSO-d6)δ5.91(s,1H),4.07(s,1H),3.81(s,2H),3.59(s,1H),3.43(s,2H),3.33(s,1H),2.26(s,1H),1.58(d,J=9.8Hz,3H),1.41(s,2H).
13C NMR(125MHz,DMSO-d6)δ171.81(s),106.71(s),79.95(s),74.33(s),69.81(s),66.68(s),44.21(s),35.56(s),33.28(s),25.85(s),21.88(s).
HRMS(ESI)m/z[M+H]+calcd for C14H17BrNO4:342.0341;found 342.0343.
实施例3 Virosaine A的O-(哌嗪基)乙基衍生物(III)的合成
将化合物II(171mg,0.5mmol)溶于20mL乙腈当中,向其中加入无水碳酸钾(690mg,5.0mmol),碘化钾(168mg,1.0mmol)和无水哌嗪(3446mg,40mmol),混合物加热回流3h。反应结束后将反应液倒入冰水中,用等量二氯甲烷萃取2次,合并有机相。依次用水和饱和食盐水洗涤合并之后的有机相,再用无水硫酸钠干燥,减压浓缩去除溶剂得到产物粗品。产物粗品用硅胶柱层析纯化(流动相为:石油醚/丙酮=100:1.0,v/v),收集棕色集中洗脱带并挥去溶剂即得到化合物III的淡棕色固体(123.2mg,71%)。
1H NMR(500MHz,DMSO-d6)δ5.90(s,1H),4.04(s,1H),3.59(s,1H),3.50(s,2H),3.40(d,J=65.9Hz,1H),2.64(s,4H),2.54(s,2H),2.31(s,4H),2.22(s,1H),1.62(s,2H),1.56(s,1H),1.43(s,2H),0.97(s,1H).
13C NMR(125MHz,DMSO-d6)δ171.84(s),106.72(s),79.94(s),74.33(s),66.72(d,J=9.2Hz),54.45(s),54.16(s),45.25(s),44.20(s),35.56(s),25.86(s),21.87(s).
HRMS(ESI):m/z[M+H]+calcd for C18H26N3O4:348.1923;found:348.1927。
实施例4 Virosaine A的O-(咪唑基)乙基衍生物(IV)的合成
将化合物II(171mg,0.5mmol)溶于25mL乙腈当中,向其中加入无水碳酸钾(690mg,5.0mmol),碘化钾(252mg,1.5mmol)和咪唑(870mg,10mmol),混合物加热回流2h。反应结束后将反应液倒入25mL冰水中,用等量二氯甲烷萃取3次,合并有机相。依次用水和饱和食盐水洗涤合并之后的有机相,再用无水硫酸钠干燥,减压浓缩去除溶剂得到产物粗品。产物粗品用硅胶柱层析纯化(流动相为:石油醚/丙酮=100:0.3,v/v),收集棕色集中洗脱带并挥去溶剂即得到化合物IV的淡棕色固体(144.1mg,71%)。
1H NMR(500MHz,DMSO-d6)δ7.86(s,1H),7.12(s,1H),6.71(s,1H),5.99(s,1H),4.09(s,1H),3.89(d,J=16.4Hz,2H),3.80(s,2H),3.58(s,1H),3.35(s,1H),2.31(s,1H),1.68(s,1H),1.58(s,2H),1.44(s,2H).
13C NMR(125MHz,DMSO-d6)13C NMR(125MHz,Common NMR Solvents)δ171.82(s),139.64(s),128.67(s),119.31(s),106.70(s),79.92(s),74.31(s),67.61(s),66.66(s),44.20(s),43.75(s),35.52(s),25.85(s),21.86(s).
HRMS(ESI):m/z[M+H]+calcd for C17H20N3O4:330.1454;found:330.1458。
实施例5组合物抗慢性阻塞性肺病实验
方法:SPF级雌性BALB/c小鼠,18-20g,随机分为正常对照组、模型对照组、药物处理组(组合物、化合物III和化合物IV 10mg/kg,灌胃给药),每组10只。将小鼠置于4L容器内,每日烟熏(南京牌香烟—红壳,焦油含量小于16mg),一周五次,连续四周,每日烟熏前1小时灌胃给药,小鼠在末次烟熏后1小时,以***钠麻醉,用0.6mL预冷的PBS缓冲液(pH7.0)肺部灌流,冲洗3次,吸出支气管肺泡灌洗液(BALF),250×g离心10min,上清用于分析TNFα、RANTES的含量。细胞用PBS缓冲液重悬,计数,细胞涂片后用瑞氏-吉姆萨染色,分析BALF中炎性细胞的变化。
组合物的制备:将研磨之后过200目网的55mg化合物III的粉末和研磨之后过200目网的45mg化合物IV的粉末装入带盖的小管中并用涡轮搅拌仪混合即得到100mg组合物,使用时用水溶解这100mg的组合物即得到组合物的溶液。
实验例1组合物对COPD小鼠支气管肺泡灌洗液(BALF)中炎症介质生成抑制作用
(1)组合物对COPD小鼠BALF中TNFα生成抑制作用
前炎性细胞因子TNFα是COPD的发病过程中的启动因子。COPD患者的TNFα水平高于正常人,培养的支气管上皮细胞与香烟的烟雾接触可分泌TNFα。TNFα可促使中性粒细胞脱颗粒,诱导起到粘膜细胞增生和高分泌,增加上皮细胞IL-8生成,增加巨噬细胞基质金属蛋白酶生成,促进气道高反应性。本实验目的在于考察组合物对COPD小鼠BALF中TNFα生成的影响,结果见表1.
表1组合物对COPD小鼠BALF中TNFα生成的影响
注:*P<0.05,与模型对照组相比;#P<0.05,与正常对照组相比。n=10。
结果:组合物在10mg/kg下对COPD模型小鼠灌胃给药,可显著降低小鼠BALF中TNFα的生成,而化合物III和化合物IV无此作用。
(2)组合物对COPD小鼠BALF中RANTES分泌抑制作用
炎症细胞的迁移受到趋化因子的调节,各种结构细胞核炎性细胞均可分泌这些小分子蛋白,COPD发病过程中RANTES分泌增加,趋化单核/巨噬细胞,T淋巴细胞,嗜酸性细胞。本实验目的在于考察组合物对COPD小鼠BALF中RANTES分泌的影响,结果见表2。
表2组合物对COPD小鼠BALF中RANTES分泌的影响
注:*P<0.05,与模型对照组相比;#P<0.01,与正常对照组相比。n=10。
结果:组合物在10mg/kg下对COPD模型小鼠灌胃给药,可降低小鼠BALF中RANTES的分泌,而化合物III和化合物IV无此作用。
实验例2组合物对COPD小鼠BALF中炎性细胞募集的抑制作用
(1)组合物对COPD小鼠BALF中中性粒细胞募集的抑制作用
中性粒细胞在COPD发病中具有重要作用,它可以释放两种丝氨酸蛋白酶,弹性蛋白酶和半胱氨酰蛋白酶-3,诱导动物产生人类肺气肿样的病理变化。中性粒细胞生命短暂,它循环招募到气道以及穿越间隙腔的过程十分迅速。病理研究证明有些COPD患者支气管组织内中性粒细胞数目增加与气流阻塞的程度有关。吸烟的COPD患者气道内中性粒细胞数目增加,特别是那些伴有慢性支气管炎的患者。影响COPD患者肺内中性粒细胞募集的主要因素为IL-8趋化活性增强。本实验目的在于考察组合物对COPD小鼠BALF中中性粒细胞募集的影响,结果见表3。
表3组合物对COPD小鼠BALF中中性粒细胞募集的影响
注:*P<0.05;#P<0.01,与正常对照组相比。n=10。
结果:组合物在10mg/kg下对COPD模型小鼠灌胃给药,可降低小鼠BALF中中性粒细胞的募集,而化合物III和化合物IV无此作用。
(2)组合物对COPD小鼠BALF中巨噬细胞募集的抑制作用
吸烟者和COPD患者肺内巨噬细胞较正常人群水平增加,多聚集在肺泡、细支气管和小气道。肺泡壁巨噬细胞数目和轻中度肺气肿以及COPD患者的小气道疾病程度呈正相关。组织病变和损伤部位可见到COPD缓慢进展和慢性病变与巨噬细胞长期增加平行。巨噬细胞可能通过释放基质金属蛋白酶导致弹性组织降解能力异常增高,诱发肺气肿的发生。本实验目的在于考察组合物对COPD小鼠BALF中巨噬细胞募集的影响,结果见表4。
表4组合物对COPD小鼠BALF中巨噬细胞募集的影响
注:*P<0.05,与模型对照组相比;#P<0.01,与正常对照组相比。n=10。
结果:组合物在10mg/kg下对COPD模型小鼠灌胃给药,可显著降低小鼠BALF中巨噬细胞的募集,而化合物III和化合物IV无此显著作用。
结论:组合物在10mg/kg下灌胃给药,对香烟诱导的小鼠慢性阻塞性肺病过程中的炎性介质的生成和趋化因子的分泌有显著抑制作用,对炎性细胞的浸润有显著的抑制,对慢性阻塞性肺病有显著的治疗作用。而化合物III和化合物IV在10mg/kg下灌胃给药,对香烟诱导的小鼠慢性阻塞性肺病过程中的炎性介质的生成和趋化因子的分泌无显著抑制作用,对炎性细胞的浸润无显著抑制,对慢性阻塞性肺病无任何治疗作用。
实施例6本发明所涉及组合物片剂的制备
取2克组合物,加入制备片剂的常规辅料18克,混匀,常规压片机制成100片。
实施例7本发明所涉及组合物胶囊的制备
取2克组合物,加入制备胶囊剂的常规辅料如淀粉18克,混匀,装胶囊制成100粒。
Claims (10)
1.一种组合物,其特征为该组合物由化合物III和化合物IV组成,该组合物中化合物III和化合物IV的质量百分数分别为55%和45%,
2.如权利要求1所述的组合物的制备方法,其特征为:将化合物III的粉末和化合物IV的粉末按照质量百分数分别为55%和45%充分混合。
3.一种如权利要求1所述的组合物在治疗慢性阻塞性肺病药物中的应用。
4.如权利要求3所述的组合物在治疗慢性阻塞性肺病药物中的应用,其特征为:所述慢性阻塞性肺病是由吸烟引起的。
5.如权利要求3所述的组合物在治疗慢性阻塞性肺病药物中的应用,其特征为:所述组合物抑制慢性阻塞性肺病过程中炎性介质的释放。
6.如权利要求5所述的组合物在治疗慢性阻塞性肺病药物中的应用,其特征为:所述炎性介质为TNFα。
7.如权利要求3所述的组合物在治疗慢性阻塞性肺病药物中的应用,其特征为:所述组合物抑制慢性阻塞性肺病过程中趋化因子的分泌。
8.如权利要求7所述的组合物在治疗慢性阻塞性肺病药物中的应用,其特征为:所述趋化因子为RANTES。
9.如权利要求3所述的组合物在治疗慢性阻塞性肺病药物中的应用,其特征为:所述组合物抑制炎性细胞的募集。
10.如权利要求9所述的组合物在治疗慢性阻塞性肺病药物中的应用,其特征为:所述炎性细胞为中性粒细胞或者巨噬细胞。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610274882.XA CN105935359A (zh) | 2016-04-28 | 2016-04-28 | Virosaine A的哌嗪基和咪唑基衍生物的组合物在抗慢性阻塞性肺病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610274882.XA CN105935359A (zh) | 2016-04-28 | 2016-04-28 | Virosaine A的哌嗪基和咪唑基衍生物的组合物在抗慢性阻塞性肺病药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105935359A true CN105935359A (zh) | 2016-09-14 |
Family
ID=57152533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610274882.XA Withdrawn CN105935359A (zh) | 2016-04-28 | 2016-04-28 | Virosaine A的哌嗪基和咪唑基衍生物的组合物在抗慢性阻塞性肺病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105935359A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015051276A1 (en) * | 2013-10-03 | 2015-04-09 | MiRx Pharmaceuticals, LLC | Small molecule securinine and norsecurinine analogs and their use in inhibiting myeloperoxidase |
-
2016
- 2016-04-28 CN CN201610274882.XA patent/CN105935359A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015051276A1 (en) * | 2013-10-03 | 2015-04-09 | MiRx Pharmaceuticals, LLC | Small molecule securinine and norsecurinine analogs and their use in inhibiting myeloperoxidase |
Non-Patent Citations (1)
Title |
---|
BING-XIN ZHAO ET AL: "Virosaines A and B, Two New Birdcage-Shaped Securinega Alkaloids with an unprecedented Skeleton from Flueggea virosa", 《ORGANIC LETTERS》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Protective effect of linarin against D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure | |
CN104095858B (zh) | 闭花木酮Cleistanone的O-(哌啶基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用 | |
Ren et al. | 5, 7, 3′-Triacetyl hesperetin suppresses adjuvant-induced arthritis in rats through modulating JAK2/STAT3 pathway | |
CN103860546A (zh) | 松香烷衍生物在炎症介质引起的疾病药物中的应用 | |
CN104147015B (zh) | 闭花木酮Cleistanone的二乙胺衍生物在制备抗慢性阻塞性肺病药物中的应用 | |
CN105037464A (zh) | 一种植物黄酮类化合物及其制备方法与应用 | |
CN105935359A (zh) | Virosaine A的哌嗪基和咪唑基衍生物的组合物在抗慢性阻塞性肺病药物中的应用 | |
CN105935362A (zh) | Virosaine A的四氢吡咯基和吗啉基衍生物的组合物在抗慢性阻塞性肺病药物中的应用 | |
CN104398525B (zh) | 闭花木酮的o-(哌嗪基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用 | |
CN105287469A (zh) | 一种组合物及其在抗慢性阻塞性肺病药物中的应用 | |
CN104857004A (zh) | 闭花木酮的o-(苯并咪唑基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用 | |
CN104644648A (zh) | 闭花木酮的o-(***基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用 | |
CN106074519A (zh) | Artalbic acid衍生物的组合物用于制备抗慢性阻塞性肺病药物 | |
CN104873504A (zh) | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用 | |
CN105998007A (zh) | Salviskinone A衍生物的组合物在抗慢性阻塞性肺病药物中的应用 | |
CN106074533A (zh) | 阿掏比克酸***基与1h‑四氮唑基衍生物的组合物用于制备抗慢性阻塞性肺病药物 | |
CN105250274A (zh) | 一种组合物及其在抗慢性阻塞性肺病药物中的应用 | |
CN105287574A (zh) | 组合物及其在抗慢性阻塞性肺病药物中的应用 | |
CN106074482A (zh) | Artalbic acid的衍生物的组合物用于制备抗慢性阻塞性肺病药物 | |
CN105343038A (zh) | 一种组合物及其在抗慢性阻塞性肺病药物中的应用 | |
CN105343088A (zh) | 组合物及其在抗慢性阻塞性肺病药物中的应用 | |
CN106074513A (zh) | Schiglautone A 衍生物的组合物用于制备抗慢性阻塞性肺病药物 | |
CN105287560A (zh) | 一种组合物及其在抗慢性阻塞性肺病药物中的应用 | |
CN105287514A (zh) | 组合物及其在抗慢性阻塞性肺病药物中的应用 | |
CN105125554A (zh) | 组合物及其在抗慢性阻塞性肺病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160914 |